Placeholder Banner

Letter to Congress Re Tax Treatment of R&D Expenses

October 11, 2022

Nearly 400 companies and trade associations wrote House and Senate leaders about the need to reverse a harmful tax change--a new requirement to amortize R&D expenses--that threatens jobs and innovation.

Download Full Comments Below
Coalition Letter on Tax Treatment of R&D Expenses

Nearly 400 companies and trade associations wrote House and Senate leaders about the need to reverse a harmful tax change--a new requirement to amortize R&D expenses--that threatens jobs and innovation.

Discover More
As organizations representing America’s highly innovative and competitive food and agricultural value chain, we write to express our thanks for USTR’s announcement that it will begin technical consultations with Mexico concerning its action to ban…
BIO’s comments on specific aspects of CMS’s Proposed Rule on Medicaid drug pricing are presented below.